东南亚市场再下一城:上海医药附属公司利伐沙班片在泰国获批上市

财中社
May 07

5月7日,上海医药(601607/02607)发布公告,公司下属常州制药厂有限公司生产的利伐沙班片收到泰国食品药品监督管理局颁发的药品注册证书,该药品获得批准上市。  利伐沙班片主要用于降低非瓣膜性房颤患者卒中和全身性栓塞的风险、治疗和预防深静脉血栓形成、用于治疗肺栓塞及预防急性病患者静脉血栓栓塞等。  截至本公告日,公司针对该药品在东南亚市场上市另投入的研发费用约324.82万元。  2026年...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10